Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-NHL
NCT06251180Phase 1Active, not recruiting
- Sponsor
- Lupeng Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rocbrutinib in B-cell non-Hodgkin lymphoma (4 arms), sponsored by Lupeng Pharmaceutical. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose up to 1.5 years and 7 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
rocbrutinib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06251180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06251180.